OPTIMIZATION OF RP-HPLC METHOD FOR DETERMINATION OF ALOGLIPTIN BENZOATE IN BULK AND DOSAGE FORM

SHUBHANGI C. DASWADKAR*, MADHUMITA A. ROY, SANJAY G. WALODEa and C. B. MAHENDRA KUMARB

Department of Pharmaceutical Chemistry, Padm. Dr. D. Y. Patil College of Pharmacy, Akurdi, PUNE – 411044 (M.S.) INDIA

aDepartment of Pharmaceutical Chemistry, Sinhgad Institute of Pharmaceutical Sciences, Kusgaon (Bk), Lonavala, PUNE – 410401 (M.S.) INDIA

bDepartment of Pharmaceutical Chemistry, St. Mary’s College of Pharmacy, H. No. 9-1-248, St. Francis Street, SECUNDERABAD – 500025 (A.P.) INDIA

ABSTRACT

A simple, economic, selective, precise, and stability-indicating HPLC method has been developed and validated for estimation of Alogliptin benzoate in bulk drug and tablet dosage form. The drug was separated using a mobile phase acetonitrile: water, (40:60 v/v) on an Agilent, TC C18 (250 × 4.6 mm) 5 μm column at flow rate of 1.0 mL min⁻¹ at ambient temperature and detection was performed at 277 nm. The detector linearity was established in concentrations ranging from 5-50 μg mL⁻¹, the regression coefficient was 0.9997. For stability study, the drug was exposed to the stress conditions such as acid, base, oxidation, neutral and sunlight as per the recommendations of ICH guidelines. The results of the analysis were validated in terms of specificity, limit of detection, limit of quantification, linearity, precision and accuracy. As per ICH guidelines results were found to be satisfactory. The method was proved to be robust with respect to changes in flow rate and temperature. The high recovery and low relative standard deviation confirm the suitability of these methods can be employed for the routine analysis of tablet containing Alogliptin.

Key words: Alogliptin benzoate, Stability study, ICH, Validation, Bulk drug.

INTRODUCTION

Recent years, diabetes has been a serious disease affecting the patients around the world. According to International Diabetes Federation (IDF), there are totally 382 million diabetes patients in 2013 and this number will rise to 592 million by 2035¹. Type 2 diabetes

¹Author for correspondence; E-mail: shubhangi1485@rediffmail.com; Mo.: +91-9860944805
is a chronic disease and progressive disease usually characterized by resistance of insulin and dysfunction of β-cell\textsuperscript{2-4}. Dipeptidyl peptidase-4 (DPP-4) is an enzyme, which is widely distributed in living organisms and blood circulation and could inactivate endogenous glucagon-like peptide-1 (GLP-1), an insulintropic hormones playing an important role in promoting insulin secretion, inhibiting glucagon secretion, delaying gastric emptying, enhancing satiety and moderating food intake\textsuperscript{5-9}.

Alogliptin benzoate, 2-[6-[3(R)-Aminopiperidine-1-yl]-3-methyl-2, 4-dioxo-1, 2, 3, 4-tetra hydropyrimidin-1-yl methyl] benzonitrile Benzoate, is a novel, potent and highly selective DPP-4 inhibitor\textsuperscript{10}.

![Chemical structure of alogliptin benzoate](image.png)

**Fig. 1: Chemical structure of alogliptin benzoate**

Very few analytical methods have been reported for the analysis of Alogliptin benzoate as single component in formulation\textsuperscript{11-15}. The main objective of the proposed work was to develop a simple, accurate, precise and sensitive RP-HPLC method for the estimation of alogliptin benzoate in bulk drug and tablet dosage form. The method was further optimized and validated in accordance with guidelines suggested by International Conference on Harmonization (ICH)\textsuperscript{16}.

**EXPERIMENTAL**

**Materials and methods**

Authenticate sample of alogliptin benzoate purchased from Swapnroop Drugs Pvt. Ltd., Aurangabad. HPLC grade water and acetonitrile (Merck Ltd., Mumbai, India) was used as solvent. All the aqueous reagents were prepared using carbon dioxide free distilled water.

**Instrumentation**

The HPLC system, Agilent 1120 compact with manual Rheodyne injector facility operates at 20 μL capacity per injection was used. The column was used Agilent TC C\textsubscript{18}.
(250 x 4.6 mm) 5 μm and the detector consisted of UV/VIS operated at 277 nm. The data were acquired and processed using EZ Chrom Elite Compact software.

**Chromatographic conditions**

Optimizations of chromatographic conditions were carried out using water: acetonitrile (60:40 v/v) as mobile phase. Prior to deliver into the system, mobile phase was filtered through 0.45 μm filter and sonicate for 10 min. The samples were introduced by injector with a 20 μL sample loop. The analysis was carried out under gradient conditions using flow rate 1.0 mL min⁻¹ at 18°C and chromatograms were recorded at 277 nm.

**Preparation of standard stock solution**

Weighed accurately 10 mg of alogliptin and transferred to 100 ml volumetric flask, add 25 mL of mobile phase and sonicate for 15 min and volume was made up to mark with mobile phase (100 μg mL⁻¹).

**Preparation of standard solution**

From the standard stock solution 1mL solution was pipetted out in 10 mL volumetric flask and volume was made up to the mark with mobile phase to get a final concentration 10 μg mL⁻¹.

**Preparation of sample solutions**

Twenty tablets of Alogliptin were weighed, triturated, mixed thoroughly and average weight of tablet was calculated. Accurately weighed quantity of tablet powder equivalent to 25 mg of Alogliptin (label claim) was transferred to 10 mL volumetric flask, added 5 mL of mobile phase and sonicate for 10 min. The resultant solution was filtered through 0.45 μ membrane filter, diluted to volume with mobile phase. 0.04 mL of resultant solution further diluted to 10 mL and injected to HPLC system (Table 1).

**Table 1: Assay of marketed formulation**

<table>
<thead>
<tr>
<th>S. No.</th>
<th>Formulation</th>
<th>Taken amount</th>
<th>Amount estimated</th>
<th>% Estimated</th>
<th>% RSD</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Nesina</td>
<td>25 mg</td>
<td>25.05 mg</td>
<td>100.2</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td></td>
<td>25 mg</td>
<td>24.97 mg</td>
<td>99.88</td>
<td>0.105</td>
</tr>
<tr>
<td>3</td>
<td></td>
<td>25 mg</td>
<td>25.01 mg</td>
<td>100.04</td>
<td></td>
</tr>
<tr>
<td>Mean</td>
<td></td>
<td></td>
<td>25.01 mg</td>
<td>100.04</td>
<td></td>
</tr>
</tbody>
</table>

RSD is Relative standard deviation
System suitability

System suitability parameters were evaluated from retention times, tailing factor, capacity factor and theoretical plates of standard chromatograms (Table 2).

Validation

Limit of detection (LOD) and limit of quantification (LOQ)

The signal-to-noise ratio ($S/N$) method was adopted for the determination of limit of detection and limit of quantification. The limit of detection was estimated as three times the $S/N$ ratio and the limit of quantification was estimated as ten times the $S/N$ ratio (Table 2).

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Values</th>
</tr>
</thead>
<tbody>
<tr>
<td>Limit of detection ($\mu g \text{ mL}^{-1}$)</td>
<td>0.271</td>
</tr>
<tr>
<td>Limit of quantification ($\mu g \text{ mL}^{-1}$)</td>
<td>0.310</td>
</tr>
<tr>
<td>Linearity ($\mu g \text{ mL}^{-1}$)</td>
<td>5-50</td>
</tr>
<tr>
<td>Regression equation ($y = mx+c$)</td>
<td>$y = 51665 x +146840$</td>
</tr>
<tr>
<td>Correlation coefficient ($r^2$)</td>
<td>0.9997</td>
</tr>
<tr>
<td>Retention time</td>
<td>3.08</td>
</tr>
<tr>
<td>Tailing factor</td>
<td>1.05</td>
</tr>
<tr>
<td>Capacity</td>
<td>3.52</td>
</tr>
<tr>
<td>Theoretical plates</td>
<td>7430</td>
</tr>
</tbody>
</table>

Specificity

Specificity is the ability of a method to discriminate between the analyte of interest and other components that may present in the sample. The specificity of the method was evaluated to ensure separation of Alogliptin.

Linearity

Different standard solutions were prepared by diluting standard stock solution with mobile phase in the concentration range 5-50 $\mu g \text{ mL}^{-1}$. Diluted samples were injected and chromatograms (Fig. 1) were taken under standard chromatographic conditions. The peak
area was plotted against corresponding concentrations to obtain the calibration graph (Fig. 2).

![Chromatogram of standard alogliptin](image)

**Fig. 2: Chromatogram of standard alogliptin**

![Calibration plot of alogliptin](image)

**Fig. 3: Calibration plot of alogliptin**

**Precision**

Precision of analytical method was expressed in relative standard deviation (RSD) of a series of measurements. The intra-day and inter-day precisions of the proposed methods were determined by estimating the corresponding responses (i.e. three concentrations/three replicates each) of the sample solution on the same day and on three different days, respectively (Table 3).
Table 3: Precision data of alogliptin

<table>
<thead>
<tr>
<th>Parameters</th>
<th>% Estimated</th>
<th>S.D.</th>
<th>% RSD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intra-day*</td>
<td>101.10</td>
<td>0.252</td>
<td>0.089</td>
</tr>
<tr>
<td></td>
<td>100.50</td>
<td>0.137</td>
<td>0.028</td>
</tr>
<tr>
<td></td>
<td>100.72</td>
<td>0.155</td>
<td>0.023</td>
</tr>
<tr>
<td>Inter-day*</td>
<td>100.15</td>
<td>0.176</td>
<td>0.070</td>
</tr>
<tr>
<td></td>
<td>100.20</td>
<td>0.185</td>
<td>0.038</td>
</tr>
<tr>
<td></td>
<td>99.98</td>
<td>0.184</td>
<td>0.027</td>
</tr>
</tbody>
</table>

Recovery

To check the accuracy of the proposed method, recovery studies were carried out by standard addition method. A known amount of standard alogliptin corresponding to 80, 100 and 120% of the label claim was added to preanalysed sample of tablet. The recovery studies were carried out in triplicate at each level (Table 4).

Table 4: Recovery study data

<table>
<thead>
<tr>
<th>Level of standard addition (%)</th>
<th>Amount of tablet powder (mg)</th>
<th>Amount of pure drug added (mg)</th>
<th>Amount of pure drug recovered (mg)</th>
<th>% Recovery</th>
<th>% RSD</th>
</tr>
</thead>
<tbody>
<tr>
<td>80</td>
<td>25</td>
<td>8</td>
<td>8.03</td>
<td>100.38</td>
<td>0.1540</td>
</tr>
<tr>
<td>100</td>
<td>25</td>
<td>10</td>
<td>10.07</td>
<td>100.70</td>
<td>0.1291</td>
</tr>
<tr>
<td>120</td>
<td>25</td>
<td>12</td>
<td>12.06</td>
<td>100.50</td>
<td>0.1735</td>
</tr>
</tbody>
</table>

Robustness

Robustness is a measure of the performance of a method when small and deliberate changes are made to the conditions of method. Robustness studies were performed by making slight variations in flow rate and mobile phase composition changes one at a time (Table 5).

Table 5: Robustness data for alogliptin

<table>
<thead>
<tr>
<th>Parameters</th>
<th>% Recovery</th>
<th>S.D.</th>
<th>% RSD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Change in mobile phase composition (60:40 ± 2)</td>
<td>99.98</td>
<td>0.325</td>
<td>0.06</td>
</tr>
</tbody>
</table>

Cont…
Parameters | % Recovery | S.D. | % RSD
--- | --- | --- | ---
Change in floe rate | 100.04 | 0.147 | 0.11
(1.0 ± 0.2 mL min⁻¹)

**Forced degradation**

**Acid and base induced degradation product**

To 10 mL of standard stock solution, 10 mL of 0.1 N HCl and 10 mL of 0.01 N NaOH were added separately. These mixtures were reflux separately for 45 min for acid and 10 min for base at 50°C. The forced degradation study in acidic and basic media was performed in the dark in order to leave out the possible degradative effect of light. 0.1 mL of each resultant solution was diluted to 10 mL with the mobile and resultant solution injected into the system.

**Hydrogen peroxide induced degradation product**

To 10 mL of standard stock solution, 10 mL of hydrogen peroxide (H₂O₂) (3% v/v) was added. This solution was heated in boiling water bath for 10 min to remove completely the excess of hydrogen peroxide and reflux for 20 min at 50°C. 0.1 mL of resultant solution was diluted to 10 mL with the mobile phase and resultant solution injected into the system.

**Neutral hydrolysis**

10 mL of standard stock solution was mixed with 10 mL water and reflux for 60 min at 60°C. 0.1 mL solution this solution was diluted to 10 mL with the mobile and resultant solution injected into the system.

**Photolytic induced degradation product**

10 mL of standard stock solution was exposed to direct sunlight for 30 min on a wooden plank and kept on terrace. 0.01 mL of resultant exposed solution was transferred to 10 mL volumetric flask, diluted with the mobile phase and solution was injected into the system.

*Indicates mean of three replicates, SD is standard deviation.
Table 6: Summary of force degradation data

<table>
<thead>
<tr>
<th>Sample stress condition</th>
<th>Stress condition</th>
<th>Alogliptin (R.T.)</th>
<th>Degradants (R.T.)</th>
<th>% Area decreased</th>
<th>Fig. No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acid degradation</td>
<td>0.1 N HCl reflux for 45 min</td>
<td>3.04</td>
<td>4.67</td>
<td>34.10</td>
<td>4</td>
</tr>
<tr>
<td>Alkaline degradation</td>
<td>0.01 N NaOH reflux for 10 min</td>
<td>3.08</td>
<td>4.83</td>
<td>6.90</td>
<td>5</td>
</tr>
<tr>
<td>Oxidative degradation</td>
<td>6% H2O2 reflux for 20 min</td>
<td>3.06</td>
<td>4.15</td>
<td>27.52</td>
<td>6</td>
</tr>
<tr>
<td>Neutral hydrolysis</td>
<td>Purified water reflux for 1 hr</td>
<td>3.08</td>
<td>4.12</td>
<td>9.46</td>
<td>7</td>
</tr>
<tr>
<td>Photolytic degradation</td>
<td>Kept in sunlight for 30 min</td>
<td>3.08</td>
<td>--</td>
<td>--</td>
<td>8</td>
</tr>
</tbody>
</table>

Fig. 4: Chromatogram of acid [0.1 N HCl (reflux for 45 min at 50°C)] treated

Sample Peak 1, Alogliptin [Rt = 3.04]; Peak 2, degradant [Rt = 4.67]

RESULTS AND DISCUSSION

The parameters were focused for improvisation of retention time, separation of degradation products and column life. The Agilent TC C18 column provided good peak shapes and no peak splitting was observed. Alogliptin showed linear responses in concentrations level ranging from 5-50 µg mL⁻¹ with correlation co-efficient 0.9996 (Table 2).
Fig. 5: Chromatogram of base [0.01 N NaOH (reflux for 10 min at 50°C)]
treated sample

Peak 1, Alogliptin [Rt = 3.08]; Peak 2, degradant [Rt = 4.83]

Fig. 6: Chromatogram of hydrogen peroxide [3% H₂O₂ (reflux for 20 min at 50°C)]
treated sample

Peak 1, Alogliptin [Rt = 3.06]; Peak 2, degradant [Rt = 4.15]

The measurement at three different concentration levels showed low value of % R.S.D. (< 2) and low value of S. E. (< 2) for intra- and inter-day variation, which suggested an excellent precision of the method.

The recovery of drug was determined by spiking drug at three different levels and was found to be between 100.38 - 100.70. The method was found to be robust with respect
to flow rate and change in mobile phase composition without any changes in system suitability parameters.

![Chromatogram of neutral hydrolysis (reflux for 60 min at 60°C)](image)

**Fig. 7: Chromatogram of neutral hydrolysis (reflux for 60 min at 60°C)**

Peak 1, Alogliptin [Rt = 3.08]; Peak 2, degradant [Rt = 4.12]

![Chromatogram of sunlight exposed (for 30 min) sample](image)

**Fig. 8: Chromatogram of sunlight exposed (for 30 min) sample**

Peak 1, Alogliptin [Rt = 3.08]

Forced degradation of drug was carried out as per the ICH guidelines (ICH Q2B) by subjecting alogliptin to various stress conditions. The percent area decreased at the level of 6.90-34.10% and additional peaks at retention time different to that of well separated peak of alogliptin indicated that alogliptin undergoes degradation in acidic, basic, oxidative and neutral conditions. Summary of force degradation data are given in Table 6.
CONCLUSION

The proposed method is highly sensitive, reproducible, specific and rapid. The method was completely validated showing satisfactory data for all the method validation parameters tested. As the method able to separate the parent drug from degradation products it can be employed as a stability indicating method for alogliptin.

REFERENCES

9. C. F. Deacon, M. A. Nauck and M. Toft-Nielsen, Both Subcutaneously and Intravenously Administered Glucagonlike Peptide I are Rapidly Degraded from the NH₂-Terminus in Type II Diabetic Patients and in Healthy Subjects, Diabetes, 44(9), 1126-1131 (1995).


Accepted: 30.12.2015